WSI Reports 23.1 Billion KRW in Cumulative Sales for 3Q... "Increase in Sales of Key Products"

WSI, a specialized company in pharmaceutical and medical device distribution, achieved external growth in the third quarter due to strong sales of its main products.

On the 15th, WSI announced that its cumulative consolidated sales for the third quarter increased by 15.4% year-on-year to 23.1 billion KRW. Operating profit for the same period was 2.9 billion KRW, and net profit was 2.0 billion KRW.

Consolidated sales for the third quarter amounted to 7.9 billion KRW, up 12.3% compared to the same period last year. Operating profit and net profit for the same period were 800 million KRW and 100 million KRW, respectively.

The increase in sales volume of the flagship product, topical hemostatic agents, led to sales growth. Medical devices such as spinal endoscopes, bone hemostatic agents, and cervical artificial discs also contributed to improved performance.

A company representative stated, "From the fourth quarter, sales from the cardiovascular interventional procedure business segment will be fully reflected, leading to higher external growth. We will actively pursue mid- to long-term growth engines through business diversification, including surgical robot business and cardiovascular interventional procedure business."

Meanwhile, WSI is actively expanding its business in the cardiovascular disease interventional procedure field. To this end, in August, it signed an exclusive domestic distribution contract for catheters including PICC (peripherally inserted central catheter) with the UK medical device company KIMAL PLC. In October, it also established a strategic partnership with LifeTech Scientific Corp, a leading company in the cardiovascular interventional procedure field based in China.

This content was produced with the assistance of AI translation services.